Guardant Health shares plunged 27% after it released disappointing blood test results - Silicon Valley Business Journal

📆 12/17/2022 2:32 AM
📰 svbizjournal

⏱ Reading Time:
22 sec. here
2 min. at publisher
📊 Quality Score:
News: 12%
Publisher: 59%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Guardant Health released test results showing its blood test accurately detected colorectal cancer or precancer 83% of the time.

Dec 16, 2022, 4:32pm PST

The results indicate Guardant's test won't be an adequate substitute for colonoscopies or Cologuard, a screening that looks for signs of cancer in patients' stool, Jeffries analyst Brandon Couillard told Bloomberg. Cologuard maker Exact Sciences Inc. says its test is 92% accurate at detecting colon cancer., down $11.20 a piece. Earlier in the session, its shares were down as much as $13.51, or 32%.

Write Comment

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Guardant Health stock plunges, Exact Sciences stock soars after colorectal-cancer test study resultsShares of Guardant Health Inc. undefined tanked 40% and shares of Exact Sciences Corp. undefined rallied more than 25% in the extended session Thursday after...
Source: MarketWatch - 🏆 3. / 97 Read more »